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Background: Treatment options for patients with locally advanced pancreatic cancer include surgery,
chemotherapy as well as radiotherapy. In many cases, surgical resection is not possible, and therefore treatment
alternatives have to be performed. Chemoradiation has been established as a convincing treatment alternative for
locally advanced pancreatic cancer. Carbon ions offer physical and biological characteristics. Due to their inverted
dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of
normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological
effectiveness (RBE), which can be calculated between 1.16 and 2.46 depending on the pancreatic cancer cell line as
well as the endpoint analyzed. Japanese Data on the evaluation of carbon ion radiation therapy showed promising
results for patients with pancreatic cancer.
Methods and design: The present PHOENIX-01 trial evaluates carbon ion radiotherapy using the active
rasterscanning technique in patients with advanced pancreatic cancer in combination with weekly gemcitabine and
adjuvant gemcitabine. Primary endpoint is toxicity, secondary endpoints are overall survival, progression-free
survival and response.
Discussion: The physical and biological properties of the carbon ion beam promise to improve the therapeutic
ratio in patients with pancreatic cancer: Due to the inverted dose profile dose deposition in the entry channel of
the beam leads to sparing of normal tissue; the Bragg peak can be directed into the defined target volume, and
the sharp dose fall-off thereafter again spares normal tissue behind the target volume. The higher RBE of carbon
ions, which has been shown also for pancreatic cancer cell lines in the preclinical setting, is likely to contribute to
an increase in local control, and perhaps in OS. Early data from Japanese centers have shown promising results. In
conclusion, this is the first trial to evaluate actively delivered carbon ion beams in patients with locally advanced
pancreatic cancer within a dose-escalation strategy.
Trial registration: NCT01795274Background
Cancer of the pancreas is the fourth most common
cause of cancer-related death in men and women. Ductal
adenocarcinoma is the most common variant in over
90% of all pancreatic malignancies. Patients commonly
present with syptoms such as weight loss, jaundice, pain,
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reproduction in any medium, provided the orSurgical resection is considered the treatment of choice;
in over 80% of all patients surgery alone does not convert
into long-term tumor control. In highly specialized centers,
surgery associated mortality has been reduced to < 5%, but
even in these centers overall survival after surgery alone
remains to be around 20 months, with a five year survival
rate of about 20% [1,2]. Several studies have shown that
strong prognostic factors are resection status, presence
of lymph-node metastases, tumor size as well as tumorLtd. This is an Open Access article distributed under the terms of the Creative
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R0-resection seems for provide a major benefit as com-
pared to R1 or R2 resections.
Pancreatic cancer is commonly classified as resectable,
borderline resectable or unresectable. Interdisciplinary
discussion on a case-by-case basis is recommended for
all patients with respect to optimal treatment of patients;
individual decisions for local treatment may vary depend-
ing on tumor size, symptoms or other.
Special focus has been set on the group of patients
with non-metastasized, but locally advanced and thus non-
resectable or borderline resectable patients. In these
cases, alternatives to radical surgery must be evaluated.
In the past, chemotherapy alone was administered, usu-
ally with gemcitabine or 5-FU.
Several concepts of chemoradiation have been established,
and clincial data has shown beneficial results with ac-
ceptable toxicity. A GITSG study initially defined the
role for radiation and chemotherapy with bolus 5-FU,
comparing split-course radiotherapy with 40 Gy with
chemotherapy to radiation with 60 Gy in combination
with chemotherapy or radiation alone: Median survival
could be increased from 22.9 weeks to 42.2 weeks [7].
Subsequent studies aimed at the optimization of 5FU
application, and most contemporary studies have left the
regimen of split-course radiotherapy. Gemcitabine has also
been used as a radiation sensitizer in pancreatic cancer
[8-12], and several studies have shown that gemcitabine
and radiation seem to be equieffective to 5-FU and radi-
ation [10,13].
To date, no specific randomized trials evaluating the
effect of chemoradiation have been performed. Results
from a prospective study evaluated clinical outcome after
radiation, gemcitabine and cisplatinum in patients with
locally advanced pancreatic adenocarcinoma. The regi-
men showed acceptable toxicity, but no benefit compared
to other single-agent chemotherapeutic treatments was
shown [14]. A retrospective analysis performed by the
MD Anderson Cancer Center revealed that in resectable
patients preoperative radiation is not disadvantageous, and
since postoperative recovery often extends the time until
(about 25% of all patients) adjuvant treatment can be
initiated [15]. Several other arguments can be brought
up supporting radiochemotherapy before any surgical
resection: Likelihood of R0 resections due to tumor
shrinkage, selection of patients with more stable disease
for surgery, treatment of micrometastases at an earlier
stage and treatment of tissue not modified by surgery
and potentially more sensitive to chemotherapy and ra-
diation [9,16,17]. The MD Anderson group showed that
median survival was 21 months, 31% of all patients
demonstrated no evidence of disease, in 132 patients
treated with preoperative chemoradiation and subsequent
pancreaticoduodenectomy [15]. In our institution we haveshown that 26% of patients with locally advanced pancreatic
cancer can undergo secondary resection after gemcitabine-
based chemoradiation, and that patients with a complete
resection are associated with a relatively good long-term
prognosis [18].
The idea to bring locally advanced tumors into a re-
sectable status has been addressed explicitly in several
studies [17,19-24]. There is evidence that the rate of
margin-free resection can be increased by preoperative
chemoradiation [25]; however, no randomized trials have
confirmed this hypothesis. Palmer and colleagues could
show that gemcitabine-based chemotherapy given as
neoadjuvant therapy for potentially resectable pancreatic
cancer lead to an increase in resectability as compared
to gemcitabine alone [21]. On the other hand, some
authors have shown that even after combined radiation
and chemotherapy the rate of potentially resectable pa-
tients did not increase, and a substantial amount of
patients presented with advanced disease 4–6 weeks
after completion of radiochemotherapy, when restaging
was performed [8,26]. At the Heidelberg Center, a novel
approach of using modern intensity modulated radio-
therapy (IMRT) in combination with gemcitabine and
the EGFR-antibody cetuximab has been performed with
a comparable intent [27]. The final study results are will
be reported soon, the study has finished recruitment.
To date, within treatment recommendations for locally
advanced pancreatic cancer without distant metastases,
radiation or radiation alone can be found as possible
approaches. Besides modifying systemic treatment and
keeping photon radiation as a constant factor, new radi-
ation modalities such as particle therapy offer distinct
physical and biological characteristics and are a promis-
ing treatment alternative for patients with pancreatic
cancer potentially increasing local responses, leading to
higher local tumor control rates, higher rates of resect-
ability, as well as an increase in survival.
Proton as well as carbon ion radiotherapy are charac-
terized by an inverted depth-dose-curve, with low dose
deposition within the entry channel, and a defined high
local dose deposition in the so called Bragg Peak. There-
fore, sparing of normal tissue in front of and behind the
defined target volume is possible. More conformal dose
delivery with increased sparing of healthy surrounding
normal tissue is possible, enabling the application of higher
local doses to the target volumes. Carbon ions additionally
offer a higher biological effectiveness due to the charac-
teristic and severe radiation damages produced in target
tissues. For pancreatic cancer cell lines, RBE for carbon
ion beams values between 1.16 and 2.46 have been reported
depending on cell line and endpoint [28]. Is has been
shown that carbon ion radiotherapy leads to an increase
in local control especially in radiation resistant tumors,
such as chordomas and chondrosarcomas, adenoidcystic
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atic cancer [29].
At Japanese institutions clinical trials have been con-
ducted to evaluate carbon ion radiotherapy for pancreatic
cancer. Between 2000 and 2003, 22 patients with localized,
resectable adenocarcinoma of the pancreas were treated
with preoperative carbon-ion radiotherapy. Doses between
44.8 Gy E and 48 Gy E in single doses of 2.8 Gy E and
3.0 Gy E were applied. Local control rate was 100%, and
overall survival was 59% at 1 year. A subgroup of patients
did not receive post-radiotherapeutic resection, which
showed a significantly lower outcome (1 year overall
survival of 3%) as compared to patients receiving surgery
(86% overall survival at 1 year [30]). This was followed
by a more hypofractionated regimen in a study with
comparable inclusion criteria, increasing applied dose
from 30 Gy E to 35.2 Gy E in 8 fractions. Still, no local
tumor recurrences were observed, and overall survival
at 1 and 5 years in patients treated with surgical resec-
tion after preoperative carbon ion radiotherapy was 89%
and 51% [30]. Patients with locally advanced and in the
first step inoperable pancreatic cancer were included
into a Phase I/II trial. Inclusion criteria included patients
with histologically confirmed ductal carcinoma of the
pancreas, volume of 14 cm or less in diameter, inoper-
able lesions; patients were treated with increasing doses
from 38.4 Gy E to 52.8 Gy E in 12 fractions. Overall sur-
vival at 1 year was 60% with a local control rate of 81%,
and patients receiving higher doses showed a significant
benefit in local control and overall survival [30]. In ana-
logy to treatment schedules with photons, also the com-
bination of chemotherapy with gemcitabine and carbon
ions was transferred into a trial protocol: In the first
part, a carbon ion dose of 43.2 Gy E in 12 fractions was
set as constant, weekly gemcitabine was increased from
400 mg/m2 to 1000 m2. Acute hematological toxicity
as well as non-hematological side effects were low, no
grade 4 and 5 toxicities were observed. Only in the
700 mg/m2 and 1000 mg/m2 gemcitabine arm, 3/6 (50%)
and 8/12 (75%) developed grade III hematological toxicity.
In all three treatment arms local control was comparable
during follow up, but survival was higher with increasing
doses of chemotherapy. At present a constant dose of
gemcitabine at 1000 mg/m2 is applied with a carbon ion
dose escalated to 50.4 Gy E [30].
Therefore, in the present PHOENIX-01 trial, carbon
ion radiotherapy using the active rasterscanning tech-
nique will be evaluated in patients with advanced pan-
creatic cancer in combination with weekly gemcitabine
and adjuvant gemcitabine.
Methods and design
The purpose of the trial is to evaluate carbon ion radiother-
apy in patients with locally advanced pancreatic cancer.With respect to toxicity, the optimal dose of carbon ion
radiotherapy will be determined. Therefore, the primary
endpoint is toxicity, secondary endpoints are evaluation
of progression-free survival, response, and overall sur-
vival after carbon ion radiotherapy.
Focus of the analysis is to evaluate safety and efficacy
of carbon ion radiotherapy in patients with locally ad-
vanced pancreatic cancer. Therefore, the aim of the trial
is to observe low rates of toxicity with high local doses
due to effect of the altered biology of carbon ions on
pancreatic cancer cells as well as the superior physical
characteristics.
The primary objective is toxicity of carbon ion radio-
therapy. As secondary objectives, imaging response,
progression-free survival and overall survival were de-
fined. The trial will be performed as a single-center
single-armed Phase I study. Informed consent will be
obtained by all patients.
Treatment schedule
Patients fulfilling the inclusion criteria will be included into
the following Phase I dose escalation treatment scheme:
Step 1: 14 × 3 Gy E 42 Gy E
Step 2: 15 × 3 Gy E 45 Gy E
Step 3: 16 × 3 Gy E 49 Gy E
Step 4: 17 × 3 Gy E 51 Gy E
Step 5: 18 × 3 Gy E 54 Gy E
Standard chemotherapy with gemcitabine (GEM)
300 mg/m2 will be continued during the radiation treat-
ment. The trial scheme is shown in Figure 1.
Study endpoints and trial duration
The primary endpoint is acute toxicity of carbon ion
radiotherapy observed within 3 months of study treat-
ment. Patients are scheduled for follow-up visits every
4 weeks after completion of carbon ion radiotherapy for
the first 3 months, thereafter in 2-months intervals or as
needed clinically including contrast-enhanced CT or MRI
as well as thorough clinical-neurological and haemato-
logical assessment. PET imaging can be scheduled to add-
itionally assess tumor response. These follow-up visits are
in line with standard care outside of clinical trials. The last
patient included into the study will be followed for at least
3 months after study treatment. This is considered the
final study visit.
Patient selection
A maximum of 33 patients should be enrolled in the
clinical trial.
Patients with the diagnosis of locally advanced pancre-
atic cancer will be evaluated and screened for the protocol.
Figure 1 PHOENIX-01-Trial scheme.
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will be informed about the study.
Inclusion criteria
Patients meeting all of the following criteria will be con-
sidered for admission to the trial:
– histologically confirmed locally advanced pancreatic
cancer or imaging defined pancreatic cancer
combined with elevated CA-19-9
– macroscopic tumor after biopsy
– age ≥ 18 years of age
– Karnofsky Performance Score ≥60
– for women with childbearing potential, (and men)
adequate contraception (sexual abstinence, estrogen-
or gestagen containing contraceptive medication etc.)
– female participants: No pregnancy present
(pregnancy test required)
– ability of subject to understand character and
individual consequences of the clinical trial
– written informed consent (must be available before
enrolment in the trial)
Exclusion criteria
Patients presenting with any of the following criteria will
not be included in the trial:
– distant metastases
– refusal of the patients to take part in the study
– previous radiotherapy of the abdomen
– patients who have not yet recovered from acute
toxicities of prior therapies
– known carcinoma < 5 years ago (excluding
Carcinoma in situ of the cervix, basal cell
carcinoma, squamous cell carcinoma of the skin)
requiring immediate treatment interfering with
study therapy– pregnant or lactating women
– participation in another clinical study or observation
period of competing trials, respectively
Radiation therapy: treatment planning & dose prescription
For particle therapy, patients will be immobilized using
an individually manufactured body fixation or position-
ing device including abdominal pressure plates as de-
scribed in detail previously [31]. For treatment planning,
contrast-enhanced CT (3 mm slice thickness) as well as
MR-imaging will be performed for optimal target defin-
ition. 4D-CT-imaging is considered standard of care for
target definition when treating patients with moving or-
gans. Additionally, PET examinations may be included
into target volume definition for treatment planning.
Organs at risk such as the intestines, stomach, lungs,
kidney, spleen and spinal cord will be contoured. Dose
constraints of normal tissue will be respected according
to Emami et al. [32].
The Gross Tumor Volume (GTV) will be defined as
the area of solid macroscopic tumor contrast enhance-
ment on CT and MR-imaging and/or PET positive areas.
The Clinical Target Volume (CTV) will be defined as
the GTV plus a margin of at least 5 mm, however, in-
cluding the regional lymph nodes and any areas of
microscopic spread.
The Planning Target Volumes (PTVs) will include the
CTV plus a safety margin accounting for organ motion
and setup inaccuracies. This margin will depend on the
immobilization system as well as the technical features
for motion compensation, i.e. gating, rescanning etc.
Proton and Carbon ion RT planning is performed using
the treatment planning software PT-Planning (Siemens,
Erlangen, Germany) including biologic plan optimization.
Biologically effective dose distributions will be calculated
using the a/ß ratio for pancreatic cancer as well as for the
endpoint late toxicity.
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ment are allowed.
Patient positioning prior to particle therapy will be
evaluated by comparison of x-rays to the DRRs. Set up
deviations >3 mm are corrected prior to radiotherapy.
The intensity-controlled rasterscanning system will be
used for beam application. Treatment planning aims in
the coverage of the PTV by the 90%-isodose line. Dose
specification is based on biologic equivalent dose be-
cause of the high relative biologic effectiveness (RBE) of
carbon ions, which differs throughout the target volume
due to its dependence on various factors. RBE will be
calculated at each voxel throughout the target volumes
and biological optimization will be performed. The dose
prescription used is related to the isoeffective dose Gy E
(Cobalt Gray equivalent) using daily fractions of 2 Gy
and a weekly fractionation of 5 × 2 Gy.
Follow-up
Regular follow-up visits will be scheduled every 4 weeks
after completion of study treatment for the first 3 months,
thereafter in 2-months intervals or as required clinically.
After completion of study treatment, treatment of pa-
tients with gemcitabine is recommended. Any systemic
treatment or chemotherapy is not part of the clinical trial.
Evaluation of surgical resection will be performed 4 weeks
after completion of radio-chemotherapy in an interdiscip-
linary setting.
For tumor progression, treatment alternatives will be
evaluated and discussed interdisciplinary considering
options of resection, systemic treatment such as chemo-
therapy, a second course of radiation therapy, or other.
During follow-up, the following parameters for assess-
ment of efficacy will be evaluated:
Progression-free survival (PFS) and treatment response
Efficacy of the treatment will be recorded according to the
RECIST-Criteria (Revised Guidelines, Version 1.1,2009 [33]):
Complete response (CR) Disappearance of all target
lesions.
Partial response (PR) At least 30% decrease in the sum
of diameters of target lesions, taking a reference the
baseline sum diameters.
Progressive disease (PD) At least a 20% increase in the
sum of diameters of target lesions, taking as reference
the smallest sum on study (this includes the baseline
sum if that is the smallest on study). In addition to the
relative increase of 20%, the sum must also demonstrate
an absolute increase of at least 5 mm (Note: The ap-
pearance of one or more new lesions is also consid-
ered progression).Stable disease (SD) Neither sufficient shrinkage to qual-
ify for PR nor sufficient increase to qualify for PD, taking
as reference the smallest sum diameters while on study.
The principal investigator or study co-ordinator may be
contacted for further discussion on a case by case basis.
Overall survival (OS)
Overall survival Is a secondary endpoint of the study.
All patients will be followed until death. The duration
of survival is the time interval between initial diagnosis
(date of the pathology report) and the date of death due
to any cause. Patients not reported dead or lost to follow-
up will be censored at the date of the last follow-up
examination.
Safety parameters
This study will use the International Common Termin-
ology Criteria for Adverse Events (CTCAE) version 4.1
for toxicity and adverse event reporting. A copy or the
CTCAE can be accessed from the CTEP home page
http://ctep.cancer.gov/protocolDevelopment/electronic_
applications/ctc.htm).
Safety and toxicity of the study treatment will be eval-
uated by clinical examination, haematological evaluation
as well as imaging studies (MRI or CT).
Other parameters:
The following parameters will be collected and taken
into account in the analyses: age, Karnofsky Performance
Score, tumor extent, response to radiation therapy, CEA,
CA 19–9 and CA 125.
Study hypothesis & sample size calculation
It is the aim of this Phase I study to determine the MTD
for carbon ion radiotherapy for the treatment of advanced
pancreatic cancer. The primary endpoint is the occurrence
of a dose limiting toxicity defined as any Grade IV toxicity
according to CTCAE Version 4.1, possibly, probably or
definitely associated to study treatment and occurring
within 3 months after completion of the study treatment.
The calculation of the sample size for the PHOENIX-01
trial is based on the traditional 3 + 3 dose escalation
scheme [34] which is conducted as follows:
Patients are treated in cohorts of three each receiving
the same dose. For the assessment of a dose limiting
toxicity (see definition above) patients are observed for
3 months after application of the study treatment. If none
of the three patients of a cohort exhibits a dose limiting
toxicity, the next cohort of three patients receives the next
higher dose. Otherwise, if at least one patient of a cohort
exhibits a dose limiting toxicity, a further cohort of three
patients is treated at the same dose level without escalat-
ing the dose. If exactly one out of the six patients treated
at this dose exhibits a dose limiting toxicity, the trial
continues as planned at the next higher dose level. If
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this dose exhibit a dose limiting toxicity, the dose escal-
ation stops at that level and the next lower dose is con-
sidered as the MTD. When the escalation has stopped,
additional patients will be treated at the MTD until a
total of nine patients is reached.
The trial is conducted to determine the MTD of car-
bon ion radiotherapy by consideration of a total of five
dose levels. Therefore, the maximum sample size is 33
patients (four dose levels with a maximum of 6 patients
each and 9 patients at the MTD).
Primary endpoint to determine the MTD out of the
five investigated dose levels is any Grade IV toxicity
according to CTCAE Version 4.1, possibly, probably or
definitely associated to study treatment and occurring
within 3 months after completion of the study treatment.
Secondary endpoints are other safety data on the applied
dose levels as well as treatment response, progression-free
survival, and overall survival.
Analysis population
The analysis set for the primary endpoint consists of all
patients treated at least once with the study treatment.
A maximum total of five analysis sets (one per dose level)
will be considered. Likewise, all patients treated at least
once with the study treatment will be included in the ana-
lysis of the secondary endpoints. Additionally, a maximum
total of five analysis sets (one per dose level) will be con-
sidered to determine any differences in secondary end-
points between the dose levels applied in this study.
Statistical methods
Confirmatory analysis
No confirmatory statistical analysis will be performed. The
MTD is determined according to the traditional 3 + 3 dose
escalation scheme for Phase I trials in oncology as de-
scribed above.
Descriptive analysis
Descriptive summary tables for the pooled set of patients
as well as separated by dose level will be presented for
the baseline patient characteristics as well as for all safety
parameters. Absolute and relative frequencies are reported
for all toxicities of the CTC list (NCI CTCAE Version 4.1)
by distinguishing the grading and the assessment of the
relation to treatment. A description of the individual load
of toxicity of each patient will be given using individual
tabulations which can be supported by graphical methods
where required.
Secondary endpoints will be evaluated by calculating
appropriate measures of the empirical distribution. Fur-
thermore, methods for time-to-event data will be ap-
plied and graphical displays of Kaplan-Meier curves will
be shown.Besides the planned analyses that are performed within
the dose escalation scheme to decide about the dosage
of the next cohort, no further interim analyses are planned
within the PHOENIX-01 study.
Discussion
About one third of all patients with the primary diagno-
sis of pancreatic cancer present with non-metastasized,
locally advanced disease. Primary curative resection is rarely
possible in these patients, however, it is known that com-
plete resection of the tumor is the strongest prognostic
factor. Thus, strategies for downsizing of locally advanced
tumors have moved into focus: With radiochemotherapy
using photons, about 20-30% of all patients will become
resectable [2,18,35].
The physical and biological properties of the carbon
ion beam promise to improve the therapeutic ratio in
patients with pancreatic cancer: Due to the inverted dose
profile dose deposition in the entry channel of the beam
leads to sparing of normal tissue; the Bragg peak can be
directed into the defined target volume, and the sharp
dose fall-off thereafter again spares normal tissue behind
the target volume. The higher RBE of carbon ions, which
has been shown also for pancreatic cancer cell lines in
the preclinical setting, is likely to contribute to an in-
crease in local control, and perhaps in OS [28,30,36,37].
Early data from Japanese centers have shown convincing
results [30,37].
Based on the preclinical hypothesis as well as the
Japanese data in several indications, the PHOENIX-01
trial was designed to evaluate carbon ion radiotherapy
for patients with locally-advanced pancreatic cancer. Beam
delivery will be performed using active rasterscanning,
and the trial is designed as a dose-escalation trial.
In conclusion, this is the first trial to evaluate actively de-
livered carbon ion beams in patients with locally advanced
pancreatic cancer within a dose-escalation strategy.
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